Oxcarbazepine (Trileptal®): A new antiepileptic drug for mono- and add- on-therapy;Oxcarbazepin (Trileptal®): Ein neues antiepileptikum zur mono- und kombinationstherapie

Aktuelle Neurologie

Volumn 27, Issue 2, 2000, Pages 59-71

  Kramer C ^a  

^a SWISS EPILEPSY CENTER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CALCIUM ANTAGONIST; CARBAMAZEPINE; CIMETIDINE; DEXTROPROPOXYPHENE; ERYTHROMYCIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARTICLE; BONE MARROW TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; EPILEPSY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROTOXICITY; SEIZURE; SKIN TOXICITY;

EID: 0034036160     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1017521     Document Type: Article

References (145)

1. Gram L. Clinical experience with oxcarbazepine. Epilepsia 1994; 35, Suppl 3: S21-S22
2. Schmutz M, Brugger F, Gentsch C et al. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 1994; 35, Suppl 5: S47-S50
3. Krämer G. Long-term safety of Trileptal. Satellite Symposium "The Place of Trileptal in Epilepsy Management". 23rd International Epilepsy Congress. Prague, Czech Republic: 12.-17.9. 1999
4. Kramer L. Clinical Development Information. Symposium: Trileptal® (oxcarbazepine): A new global dossier submission. Sevilla, September 22; 1998
5. Faigle JW, Menge GP. Pharmacokinetic and metabolic features of oxcarbazepine and their clinical significance: comparison with carbamazepine. Int Clin Psychopharmacol 1990; 5, Suppl 1: 73-82
6. Bülau P, Fröscher W. Oxcarbazepine as a new antiepileptic substance. Drugs of Today 1991; 27: 51-54
7. Gram L. Oxcarbazepine. In: Engel J Jr, Pedley T (eds): Epilepsy. A Comprehensive Textbook, Volume Two. Philadelphia: Lippincott-Raven Publishers, 1997: 1541-1546
8. Grant SM, Faulds D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43: 873-888
9. Kumps A, Wurth C. Oxcarbazepine disposition: preliminary observations in patients. Biopharmaceut Drug Dispos 1990; 11: 365-370
10. Porter RJ. New developments in the search for improved antiepileptic drugs. Jap J Psychiatry Neurol 1993; 47: 145-162
11. Schmutz M, Ferrat T, Heckendorn R et al. GP 47779, the main human metabolite of oxcarbazepine (Trileptal), and both enantiomers have equal anticonvulsant activity (abstract). Epilepsia 1993; 34, Suppl 2: 122
12. Theisohn M, Heimann G. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers. Eur J Clin Pharmacol 1982; 22: 545-551
13. Anonymous. Oxcarbazepine. Lancet 1989; 2: 196-198
14. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 1993; 24: 441-452
15. Degen PH, Flesch G, Cardot J-M et al. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. Biopharmaceut Drug Dispos 1994; 15: 519-526
16. Dickinson RG, Hooper WD, Dunstan PR et al. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol 1989; 37: 69-74
17. Theisohn M, Fröscher W, Hoffmann W. Erste Behandlungsversuche mit Oxcarbazepin. In: Remschmidt H, Rentz R, Jungmann J (Hrsg): Epilepsie 1980. Stuttgart, New York: Thieme, 1981: 176-182
18. Baruzzi A, Albani F, Riva R. Oxcarbazepine: Pharmakokinetic interactions and their clinical relevance. Epilepsia 1994; 35, Suppl 3: S14-S19
19. Kälviäinen R, Jeränen T, Riekkinen PJ Sr. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs 1993; 46: 1009-1024
20. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35, Suppl 3: S10-S13
21. Augusteijn R, van Parys JAP. Oxcarbazepine (Trileptal, OXC) -Dose-concentration relationship in patients with epilepsy (abstract). Acta Neurol Scand 1990; 82, Suppl 133: 37
22. Krämer G, Theisohn M, Stoll KD et al. Oxcarbazepin versus Carbamazepin bei gesunden Probanden. Studien zur Kinetik, zu Metabolismus und Verträglichkeit. In: Kruse R (Hrsg): Epilepsie 84. Reinbek: Einhorn-Presse Verlag, 1985: 379-387
23. Larkin JG, McKee PJW, Forrest G et al. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991; 31: 65-71
24. van Parys JA, Hop W, Vulto A et al. Steady-state pharmacokinetics of oxcarbazepine in adults (abstract). Epilepsia 1998; 39, Suppl 6: 47
25. May TW, Rambeck B, Sälke-Kellermann A. Fluctuations of 10-hydroxy-carbazepine during the day in epileptic patients. Acta Neurol Scand 1996; 93: 393-397
26. Feldmann KF, Dörhöfer G, Faigle JW et al. Pharmacokinetics and metabolism of GP 47 779, the main human metabolite of oxcarbazepine (GP 47 680) in animals and healthy volunteers. In: Dam M, Gram L, Penry JK (eds): Advances in Epileptology. XIIth Epilepsy International Symposium. New York: Raven Press, 1981: 89-96
27. 14C-oxcarbazepine in man. Xenobiotica 1986; 16: 769-778
28. Sabers A, Gram L. Oxcarbazepine. In: Trimble MR (ed): New Anticonvulsants. Advances in the Treatment of Epilepsy. Chichester: Wiley & Sons, 1994: 103-112
29. Fröscher W, Krämer G, Schmidt D, Stefan H. Serumkonzentration von Antiepileptika. Praktische Richtlinien zur Messung und sinnvollen Interpretation. Nervenarzt 1999; 70: 172-177
30. Tecomas ES. Oxcarbazepine. Epilepsia 1999; 40, Suppl 5: S37-S46
31. Klitgaard NA, Kristensen O. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients. Eur J Clin Pharmacol 1986; 31: 91-94
32. Kristensen O, Klitgaard MA, Jönsson B et al. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurol Scand 1983; 68: 145-150
33. Cardot JM, Degen P, Flesch G et al. Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state. Biopharm Drug Dispos 1995; 16: 603-614
34. Menge G, Dubois JP. Determination of oxcarbazepine in human plasma by high-performance liquid chromatography. J Chromatogr 1983; 275: 189-194
35. Rouan MC, Decherf M, Le Clanche V et al. Automated microanalysis of oxcarbazepine and its monohydro and transdiol metabolites in plasma by liquid chromatography. J Chromatogr 1994; B 658: 167-172
36. Wad N, Rai PV, Egli M. Klinisch-chemische und klinisch-pharmakologische Aspekte von Mephenytoin, Methsuximide, Monohydroxy-Carbazepine (GP 47779) und Pheneturide. Jahresbericht 1979 der Schweizerischen Epilepsie-Klinik. Zürich: 1980: 23-33
37. von Unruh GE, Paar WD. Gas chromatographic/mass spectrometric assays for oxcarbazepine and its main metabolites, 10-hydroxy-carbazepine and carbazepine-10.11-trans-diol. Biomed Environm Mass Spectrometry 1986; 13: 651-656
38. Kumps A, Mardens Y. Cross-reactivity assessment of oxcarbazeptine and its metabolites in the EMIT assay of carbamazepine plasma levels. Ther Drug Monit 1986; 8: 95-97
39. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 2000; 55: 697-705
40. Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependant enzyme induction by oxcarbazepine? Eur J Clin Pharmacol 1990; 39: 187-188
41. Novartis Pharma GmbH. Fachinformation Trileptal®. Nürnberg: Februar 2000
42. Tripp S, Hundal S, Kapeghian JC et al. Evaluation of oxcarbazepine and its mono-hydroxy metabolite (GP 47779) for potential drug interactions in vitro (abstract). Epilepsia 1996; 37, Suppl 5:22
43. Arnoldussen W, Hulsman J, Rentmeester T. Interaction between oxcarbazepine and phenytoin (abstract). Epilepsia 1993; 34, Suppl 6: 37
44. McKee PJW, Blacklaw J, Forrest G et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, valproate, and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27-32
45. May TW, Rambeck B, Jürgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21: 175-181
46. Krämer G, Tettenborn B, Klosterskov Jensen P et al. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992; 33: 1145-1148
47. Fattore C, Cipolla G, Gatti G et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783-787
48. Klosterskov Jensen P, Saano V, Haring P et al. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992; 33: 1149-1152
49. Sonnen AEH. Oxcarbazepine and oral contraceptives (abstract). Acta Neurol Scand 1990; 82, Suppl 133: 37
50. Zaccara G, Gangemi PF, Bendoni L et al. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit 1993; 15: 39-42
51. Schwabe S. Oxcarbazepine: Clinical development program. Epilepsia 1994; 35, Suppl 5: S51-S53
52. Arnoldussen W, Hulsman J, Rentmeester T. Interaction of valproate and clobazam on the metabolism of oxcarbazepine (abstract). Epilepsia 1993; 34, Supp 2: 160
53. Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996; 31: 309-324
54. Tartara A, Galimberti CA, Manni R et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993; 36: 366-368
55. van Parys JAP, Meijer JWS, Segers JP. Dose-concentration proportionality in epileptic patients stabilized on oxcarbazepine: effects of co-medication (abstract). Epilepsia 1991; 32, Suppl 1: 70
56. Gross N. Retrospektive Analyse des Wirkungsspektrums, der Nebenwirkungen und der Interaktionen des Antiepileptikums Oxcarbazepin. Inaugural-Dissertation. Zürich: Medizinische Fakultät der Universität, 1997
57. Rentmeester TW, Hulsman JARJ, Glue P et al. Effects of felbamate on the pharmacokinetics of oxcarbazepine (abstract). Epilepsia 1995; 36, Suppl 3: S160
58. Pisani F, Fazio A, Oteri G et al. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta Neurol Scand 1994; 90: 130-132
59. Krämer G, Tettenborn B, Flesch G. Oxcarbazepine-verapamil drug interaction in healthy volunteers (abstract). Epilepsia 1994; 32, Suppl 1: 70-71
60. Keränen T, Jolkkonen J, Jensen PK et al. Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurol Scand 1992; 85: 239-242
61. Keränen T, Jolkkonen J, Jensen PK et al. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992; 86: 120-131
62. Morgensen PH, Jørgensen L, Boas J et al. Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites. Acta Neurol Scand 1982; 85: 14-17
63. Elwes RDC, Binnie CD. Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet 1996; 30: 403-415
64. Krämer G. Pharmacokinetic interactions of new antiepileptic drugs. In: Stefan H, Krämer G, Mamoli B (eds): Challenge Epilepsy - New Antiepileptic Drugs. Berlin: Blackwell Science, 1998: 87-103
65. Patsalos PN, Duncan JS. Antiepileptic drugs. A review of clinically significant drug interactions. Drug Safety 1993; 9: 156-184
66. Klosterskov Jensen P, Gram L, Schmutz M. Oxcarbazepine In: Pisani F, Perucca E, Avanzini G et al (eds): New Antiepileptic Drugs (Epilepsy Res, Suppl 3). Amsterdam: Elsevier, 1991: 135-140
67. Kubová H, Mareš P. Anticonvulsant action of oxcarbazepine, hydroxy carbamazepine, and carbamazepine against metrazol-induced seizures in developing rats. Epilepsia 1993; 34: 188-192
68. Wamil AW, Schmutz M, Portet C et al. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol 1994; 271: 301-308
69. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999; 40, Suppl 5: S2-S10
70. Calabresi P, de Murtas M, Stefani A et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 1995; 36: 990-996
71. Stefani A, Pisani A, de Murtas M et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-volatge-activated calcium currents. Epilepsia 1995; 36: 997-1002
72. Krämer G, Schmutz M. Oxcarbazepin. Stuttgart, New York: Thieme, 2000
73. Waldmeier PC, Baumann PA, Wicki P et al. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995; 45: 1907-1913
74. Cooper H, Schachter SC, Schomer DL. Partial onset seizures that are resistant to carbamazepine may respond to oxcarbazepine (abstract). Epilepsia 1996; 37, Suppl 5: 153
75. McLean MJ, Schmutz M, Wamil AW et al. Oxcarbazepine: mechanism of action. Epilepsia 1994; 35, Suppl 3: S5-S9
76. Dam M, Østergaard LH. Oxcarbazepine. In: Levy RH, Mattson RH, Meldrun BS (eds): Antiepileptic Drugs, Fourth Edition. New York: Raven Press, 1995: 987-995
77. Rai PV. Clinical trial for the estimation of anticonvulsive properties and side reactions of a new drug: ketocarbamazepine (abstract). In: Wada JA, Penry JK (eds): Advances in Epileptology. The Xth Epilepsy International Symposium. New York: Raven Press, 1980: 357
78. Klosterskov Jensen P. Oxcarbazepine (Trileptal®) in anti-epileptic polytherapy. Behav Neurol 1990; 3, Suppl 1: 35-39
79. van Parys JAP, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal®) on a named-patient basis. Epilepsy Res 1994; 19: 79-85
80. Egli M, Suter P, Nungässer A et al. Retrospektive Untersuchung bei mit Oxcarbazepin behandelten Patienten. Unveröffentlichter Bericht. Zürich: 1993
81. Friis ML, Kristensen O, Boas J et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-227
82. Bülau P, Stoll KD, Fröscher W. Oxcarbazepine versus carbamazepine. In: Wolf P, Dam M, Janz D et al: Advances in Epileptology. XVIth Epilepsy International Symposium. New York: Raven Press, 1987: 531-536
83. Houtkooper MA, Lammertsma A, Meyer JWA et al. Oxcarbazepine (GP 47 680): a possible alternative to carbamazepine? Epilepsia 1987; 28: 693-698
84. Reinikainen KJ, Keränen T, Halonen T et al. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987; 1: 284-289
85. Dam M. Oxcarbazepine in monotherapy. Behav Neurol 1990; 3, Suppl 1: 31-34
86. Dam M, Ekberg R, Løyning Y et al (The Scandinavian Oxcarbazepine Study Group). A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-76
87. Ciba Geigy. Trileptal®. Oxcarbazepine. A first line antiepileptic (product information). Basel: Ciba-Geigy Limited, 1994
88. Barcs G, Walker E, Elger CE et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41 : accepted for publication
89. Glauser T, Nigro M, Sachdeo R et al. Safety and efficacy of oxcarbazepine as adjunctive therapy in children with inadequately controlled partial seizures (abstract). Neurology 1999; 52, Suppl 2: A 392
90. Glauser T, Nigro M, Sachdeo R et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000; 54: accepted for publication
91. Schachter S. New polytherapy clinical trials and pre-surgical clinical trial. Symposium: Trileptal® (oxcarbazepine): A new global dossier submission. Sevilla: September 22; 1998
92. Schachter S, Vazquez B, Fisher RS et al. Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52: 732-737
93. Beydoun AA, Sachdeo R, Rosenfeld W et al. Safety and efficacy of oxcarbazepine monotherapy in patients with medically refractory partial epilepsy (abstract). Epilepsia 1998; 39, Suppl 6: 48
94. Sachdeo R. New monotherapy clinical trials, emerging AED selection issues and the role of Trileptal® (oxcarbazepine): A new global dossier submission. Sevilla: September 22, 1998
95. Sachdeo R, Beydoun A, Schachter S et al. Safety and efficacy of oxcarbazepine monotherapy (abstract). Neurology 1998; 50, Suppl 4: A200
96. Bill P, Vigonius U, Pohlmann H et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204
97. Christe W, Krämer G, Vigonius U et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451-460
98. Guerreiro M, Vigonius U, Pohlmann H et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205-213
99. Krämer G, Ganger R, Deisenhammer E et al. Double-blind, multicenter, noncomparative assessment of the retention rate of b.i.d. administration of oxcarbazepine as monotherapy for epilepsy in adults (abstract). Epilepsia 1998; 39, Suppl 6: 132
100. Krämer G, Bülau P, Blankenhorn V et al. Oxcarbazepin und Carbamazepin. Kinetik, Metabolismus, Enzyminduktion und Konsequenzen für den klinischen Einsatz. Münch med Wschr 1990; 132, Suppl 1: S71-S74
101. Besser R, Krämer G. EEG-Veränderungen unter Oxcarbazepin und Carbamazepin. In: Müller-Oerlinghausen B, Haas S, Stoll K-D (Hrsg): Carbamazepin in der Psychiatrie. Stuttgart, New York: Thieme, 1989: 160-164
102. Meier W, Besser R, Keämer G. Changes of EEG spectral parameters under the influence of oxcarbazepine (abstract). Electroenceph Clin Neurophysiol 1993; 87: 7P-8P
103. th Epilepsy International Congress, Book of Abstracts. Hamburg: September 6-9, 1985
104. Huuskonen UEJ, Tolonen U, Isojarvi IIT. Quantitative electroencephalography in patients taking oxcarbazepine for epilepsy (abstract). Epilepsia 1999; 40, Suppl 7: 170
105. Stern H, Krämer G. Einfluss von Carbamazepin und Oxcarbazepin auf periphere Nerven und Skelettmuskulatur. In: Hallen O, Meyer-Wahl JG, Braun J (Hrsg): Epilepsie 83. Reinbek: Einhorn-Presse Verlag, 1985: 154-161
106. Danner R, Partanen J, Keränen T et al. Comparison of the effects of carbamazepine and oxcarbazepine on peripheral nerve conduction. Epilepsy Res 1988; 2: 272-275
107. Zaccara G, Gangemi PF, Messori A et al. Effects of oxcarbazepine and carbamazepine on the central nervous system: computerised analysis of saccadic and smooth-pursuit eye movements. Acta Neurol Scand 1992; 85: 425-429
108. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993; 44: 529-533
109. Gillham RA, McKee PJW, Brodie MJ. Oxcarbazepine and cognitive function after a single dose and during a double-blind placebo-controlled cross-over study (abstract). Epilepsia 1993; 34, Suppl 2: 122
110. Sabers A, Møller M, Dam M et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand 1995; 92: 19-27
111. Äikiä M, Kälviäinen R, Sivenius J et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992; 11: 199-203
112. Pendlebury SC, Moses DK, Eadie MJ. Hyponatremia during oxcarbazepine therapy. HumanToxicol 1989; 8: 337-344
113. van Amselvoort T, Bakshi R, Devaux CB et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181-188
114. Johannessen AC, Nielsen OA. Hyponatremia induced by oxcarbazepine. Epilepsy Res 1987; 1: 155-156
115. Steinhoff BJ, Stoll K-D, Stodieck SRG et al. Hyponatremic coma under oxcarbazepine therapy. Epilepsy Res 1992; 11: 67-70
116. Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine-induced hyponatraemia, a cross-sectional study. Epilepsy Res 1988; 2: 269-271
117. Zakrzewska JM, Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10,11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988; 82: 110-115
118. Huuskonen UEJ, Pakarinen AJ, Moilanen E et al. The role of gender and drug metabolites in carbamazepine-or oxcarbazepine-related hyponatremia (abstract). Epilepsia 1998; 39, Suppl 6: 126
119. Huuskonen UEJ, Isojärvi JIT. Antiepileptic drugs and serum sodium (abstract). Epilepsia 1997; 38, Suppl 8: 89-90
120. Rattya J, Vainionpaa L, Knip M et al. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999; 103: 588-593
121. Isojärvi JIT, Pakarinen AJ, Rautio A et al. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol 1995; 47: 461-464
122. Isojärvi JIT, Airaksinen KEJ, Mustonen JN et al. Thyroid and myocardial function after replacement of carbamazepine by oxcarbazepine. Epilepsia 1995; 36: 810-816
123. Payne TA, Kothary S, Varma NK et al. Serum sodium and thyroid function after replacement of carbamazepine with oxcarbazepine (abstract). Epilepsia 1997; 38, Suppl 8: 94
124. Isojärvi JIT, Pakarinen AJ, Rautio A et al. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994; 35: 1217-1220
125. 12 levels during carbamazepine and oxcarbazepine therapy. Seizure 1997; 6: 207-211
126. Dam M, Jakobsen K (The Danish Oxcarbazepine Study Group). Oxcarbazepine in patients hypersensitive to carbamazepine (abstract). Acta Neurol Scand 1984; 70: 223
127. th Epilepsy International Congress, Book of Abstracts. Hamburg: September 6-9, 1985
128. Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993; 34: 163-165
129. Bülau P, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988; 34: 311-313
130. Pienimäki P, Lampela E, Hakkola J et al. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 1997; 38: 309-316
131. Andermann E. Pregnancy and oxcarbazepine (discussant statement). Epilepsia 1994; 35, Suppl 3: S26
132. Lindhout D, Omtzigt JGZ. Teratogenic effects of antiepileptic durgs: implications for the management of epilepsy in women with childbearing age. Epilepsia 1994; 35, Suppl 4: S19-S28
133. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 1995; 29: 341-369
134. Stroink H, Tang KT, van Parys JAP et al. Steady-state pharmacokinetics of oxcarbazepine in children (abstract). Epilepsia 1998; 39, Suppl 8: 48
135. Pariente-Khayat A, Tran A, Vauzelle-Kervroëdan F et al. Pharmacokinetics of oxcarbazepine as add-on therapy in epileptic children (abstract). Epilepsia 1994; 35, Suppl 8: 119
136. Gaily E, Granström ML, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol 1997; 12: 496-498
137. Borusiak P, Korn-Merker E, Holert N et al. Oxcarbazepine in treatment of childhood epilepsy: A survey of 46 children and adolescents. J Epilepsy 1998; 11: 355-360
138. Bettendorf U, Borusiak P, Weisheit C et al. Kombinationstherapie mit Valproat: Carbamazepin versus Oxcarbazepin - eine prospektive Studie (Abstract). Epilepsieblätter 1999; 12, Suppl 1: 56
139. van Heiningen P, Eve MD, Osterhuis B et al. The influence of age on the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50: 410-419
140. Borusiak P, Korn-Merker E, Holert N et al. Hyponatremia induced by oxcarbazepine in children. Epilepsy Res 1998; 30: 241-246
141. Battino D, Croci D, Granata T et al. Changes in unbound and total valproate concentrations after replacement of carbamazepine with oxcarbazepine (abstract). Epilepsia 1993; 34, Suppl 2: 160
142. Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report of two cases. Pharmacopsychiat 1996; 29: 156-158
143. Raitasuo V, Lehtovaara R, Huttonen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. Psychopharmacology 1994; 116: 115-116
144. Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994; 35, Suppl 3: S23-S25
145. Krämer G. Die neuen Antiepileptika. Akt Neurol 1998; 25: 341-350